IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today that it has added a new parameter, respiration rate from the pleth (RRp™), to its MightySat fingertip pulse oximeter. MightySat is intended for general wellness and health applications including sports, fitness, and relaxation management.
Respiration rate, or the number of breaths per minute, is infrequently measured outside of healthcare settings because it typically requires manual counting of breaths with a timer and then multiplying to convert to a per minute rate, or chest leads or straps that are not convenient to use. Fingertip pulse oximeters are being increasingly used for general wellness and health applications. Now consumers will be able to quickly and easily measure respiration rate, in addition to arterial oxygen saturation (SpO2), pulse rate (PR), perfusion index (PI), and Plethysmograph Variability Index (PVI®).
Masimo pulse oximeters are #1 in U.S. hospitals1 because they provide accurate measurements when other pulse oximeters fail, by using a revolutionary invention called Signal Extraction Technology (SET®). MightySat features hospital-grade SET pulse oximetry and also provides parameters not available on other fingertip pulse oximeters, such as RRp and PVI. In addition, MightySat offers a Bluetooth wireless interface to the Masimo Personal Health and Apple Health App to track, trend, and communicate measurements. MightySat is increasingly being used by elite athletes and teams to assess and improve performance.
“The addition of respiration rate to the MightySat is a game changer because we can now quantify breathing - a fundamental indicator of health, wellness, and sports performance,” stated Olympic Silver Medalist Dotsie Bausch.
“Sometimes matches are won by a few points, and I need every breath to count,” said Coco Vandeweghe, Professional Tennis Player on the WTA Tour. “MightySat makes breath tracking easier.”
“We believe the MightySat will help transform the wearables market by providing fitness enthusiasts with the same valuable personal data that to date has only been available to elite athletes,” said Joe Kiani, Chairman and CEO of Masimo.
“Helping athletes to improve their overall performance ecosystem is what I do,” stated Tim DiFrancesco, PT, DPT, ATC, CSCS, Head Strength and Conditioning Coach for the Los Angeles Lakers. “That requires gaining insight into the well-being of the person as well as the physiology within the person. Many objective monitoring tools fail to provide accurate and valuable information in a swift and noninvasive manner, but MightySat succeeds. After incorporating MightySat into my athlete monitoring toolbox, I see an impressive list of potential value through quantifying and measuring markers that give a more granular look at athlete readiness, fatigue/overtraining, fuel source utilization, and cardiovascular conditioning.”
This year at the Sands Expo in Las Vegas, attendees can visit Masimo at CES booth 73710 and observe MightySat measurements before and after a live audience cycling competition. Cycling participants will be aided by two experts, Stig Severinsen and Dotsie Bausch. Stig is a four-time World Champion freediver and holds multiple Guinness World Records, including history’s longest breath-hold, of 22 minutes. Dotsie is a seven-time USA Cycling National Champion, two-time Pan-American Champion, and silver medalist in team pursuit cycling at the 2012 London Olympics. Both Stig and Dotsie will also be available in the booth to answer questions about how they have incorporated MightySat into their health and fitness routines.
MightySat is available for purchase on Amazon U.S. and Amazon U.K. MightySat with Respiration Rate will be available for purchase by the end of February 2016.
@MasimoInnovates | #Masimo
- iData Research. U.S. Market for Patient Monitoring Equipment. 2014.
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. The benefits of Masimo SET® have been proven in more than 100 independent and objective studies and it is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index (ORI™), in addition to SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform designed to speed the pace of innovation and reduce the cost of care. Masimo is also taking an active leadership role in mHealth with products such as the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, those related to the expected adoption of MightySat. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our belief that Masimo's unique noninvasive measurement technologies contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.